 Jennifer Patnaik
Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Visual Acuity | 9 | 2020 | 217 | 1.940 |
Why?
| | Macular Degeneration | 3 | 2020 | 79 | 1.790 |
Why?
| | Geographic Atrophy | 3 | 2019 | 26 | 1.260 |
Why?
| | Cataract | 4 | 2020 | 133 | 1.220 |
Why?
| | Lenses, Intraocular | 2 | 2020 | 19 | 1.110 |
Why?
| | Eye Diseases | 2 | 2020 | 76 | 1.010 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 23 | 0.870 |
Why?
| | Ophthalmology | 1 | 2019 | 37 | 0.830 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 128 | 0.800 |
Why?
| | Lens, Crystalline | 1 | 2020 | 133 | 0.790 |
Why?
| | Phacoemulsification | 4 | 2020 | 62 | 0.780 |
Why?
| | Internal Medicine | 1 | 2019 | 192 | 0.720 |
Why?
| | Automobile Driving | 1 | 2018 | 103 | 0.720 |
Why?
| | West Nile Fever | 3 | 2011 | 56 | 0.710 |
Why?
| | Registries | 3 | 2019 | 1661 | 0.700 |
Why?
| | Emergency Medicine | 1 | 2019 | 270 | 0.660 |
Why?
| | Breast Neoplasms | 3 | 2011 | 1886 | 0.650 |
Why?
| | Family Practice | 1 | 2019 | 399 | 0.630 |
Why?
| | Retinal Detachment | 3 | 2019 | 49 | 0.600 |
Why?
| | Self Report | 1 | 2018 | 603 | 0.600 |
Why?
| | Commerce | 2 | 2013 | 69 | 0.550 |
Why?
| | Tobacco Products | 1 | 2013 | 51 | 0.530 |
Why?
| | Vitrectomy | 4 | 2020 | 58 | 0.520 |
Why?
| | Smoking Prevention | 1 | 2013 | 149 | 0.520 |
Why?
| | Disease Notification | 2 | 2011 | 16 | 0.470 |
Why?
| | Colorado | 16 | 2019 | 4483 | 0.460 |
Why?
| | Eye Injuries | 2 | 2021 | 46 | 0.420 |
Why?
| | Vitreous Body | 2 | 2020 | 92 | 0.420 |
Why?
| | Wet Macular Degeneration | 2 | 2019 | 23 | 0.410 |
Why?
| | Comorbidity | 2 | 2011 | 1537 | 0.410 |
Why?
| | Lens Implantation, Intraocular | 2 | 2020 | 42 | 0.410 |
Why?
| | Aged, 80 and over | 12 | 2020 | 6518 | 0.400 |
Why?
| | Cataract Extraction | 2 | 2020 | 49 | 0.400 |
Why?
| | Diabetic Retinopathy | 2 | 2020 | 144 | 0.400 |
Why?
| | Hepatitis A | 2 | 2011 | 24 | 0.370 |
Why?
| | Complement System Proteins | 2 | 2020 | 223 | 0.370 |
Why?
| | Aged | 18 | 2020 | 18934 | 0.360 |
Why?
| | West Nile virus | 1 | 2007 | 51 | 0.360 |
Why?
| | Retrospective Studies | 16 | 2020 | 10064 | 0.350 |
Why?
| | Internet | 3 | 2008 | 624 | 0.350 |
Why?
| | Follow-Up Studies | 7 | 2020 | 4685 | 0.350 |
Why?
| | Complement Activation | 2 | 2020 | 306 | 0.350 |
Why?
| | Restaurants | 1 | 2006 | 10 | 0.350 |
Why?
| | Local Government | 1 | 2006 | 30 | 0.340 |
Why?
| | Health Promotion | 1 | 2013 | 637 | 0.340 |
Why?
| | Female | 31 | 2020 | 59707 | 0.340 |
Why?
| | Humans | 41 | 2021 | 104249 | 0.330 |
Why?
| | Public Health Administration | 1 | 2006 | 84 | 0.320 |
Why?
| | Chronic Disease | 2 | 2011 | 1686 | 0.320 |
Why?
| | Ethnic Groups | 2 | 2019 | 623 | 0.310 |
Why?
| | Homosexuality, Male | 2 | 2020 | 138 | 0.280 |
Why?
| | Refraction, Ocular | 2 | 2020 | 17 | 0.270 |
Why?
| | Male | 27 | 2020 | 58392 | 0.260 |
Why?
| | Trabeculectomy | 2 | 2019 | 49 | 0.250 |
Why?
| | Odds Ratio | 4 | 2019 | 1033 | 0.250 |
Why?
| | Civil Disorders | 1 | 2021 | 6 | 0.240 |
Why?
| | Weapons | 1 | 2021 | 11 | 0.240 |
Why?
| | Political Activism | 1 | 2021 | 9 | 0.240 |
Why?
| | Corneal Transplantation | 1 | 2020 | 10 | 0.230 |
Why?
| | Cross-Sectional Studies | 4 | 2019 | 3662 | 0.230 |
Why?
| | Eye Banks | 1 | 2020 | 7 | 0.230 |
Why?
| | Retinal Drusen | 1 | 2020 | 8 | 0.230 |
Why?
| | Lens Capsule, Crystalline | 1 | 2020 | 6 | 0.230 |
Why?
| | SEER Program | 2 | 2011 | 194 | 0.230 |
Why?
| | Strabismus | 1 | 2020 | 23 | 0.220 |
Why?
| | Oculomotor Muscles | 1 | 2020 | 38 | 0.220 |
Why?
| | Cardiovascular Diseases | 1 | 2011 | 1585 | 0.220 |
Why?
| | Intraocular Pressure | 2 | 2019 | 220 | 0.220 |
Why?
| | Lasers, Excimer | 1 | 2020 | 15 | 0.220 |
Why?
| | Myopia | 1 | 2020 | 19 | 0.220 |
Why?
| | Macula Lutea | 1 | 2019 | 12 | 0.220 |
Why?
| | Scleral Buckling | 1 | 2019 | 14 | 0.220 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2019 | 11 | 0.220 |
Why?
| | Keratomileusis, Laser In Situ | 1 | 2020 | 13 | 0.220 |
Why?
| | Retinal Hemorrhage | 1 | 2019 | 20 | 0.220 |
Why?
| | Middle Aged | 15 | 2020 | 27633 | 0.220 |
Why?
| | Refugees | 1 | 2020 | 44 | 0.220 |
Why?
| | Protective Factors | 1 | 2019 | 76 | 0.210 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2020 | 58 | 0.210 |
Why?
| | Head Injuries, Closed | 1 | 2019 | 44 | 0.210 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 70 | 0.210 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 33 | 0.210 |
Why?
| | Intraoperative Complications | 1 | 2020 | 115 | 0.210 |
Why?
| | Complement C3a | 1 | 2019 | 36 | 0.210 |
Why?
| | Uveitis, Posterior | 1 | 2019 | 10 | 0.210 |
Why?
| | Risk Assessment | 3 | 2019 | 2934 | 0.210 |
Why?
| | Accreditation | 1 | 2019 | 99 | 0.210 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 44 | 0.200 |
Why?
| | Postoperative Period | 4 | 2020 | 306 | 0.200 |
Why?
| | Patient Care | 1 | 2019 | 91 | 0.200 |
Why?
| | Complement Factor B | 1 | 2019 | 86 | 0.200 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2018 | 18 | 0.190 |
Why?
| | Retinopathy of Prematurity | 1 | 2019 | 70 | 0.190 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 250 | 0.190 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2019 | 189 | 0.180 |
Why?
| | United States | 7 | 2021 | 11035 | 0.180 |
Why?
| | Sexually Transmitted Diseases | 3 | 2004 | 194 | 0.180 |
Why?
| | Glaucoma, Open-Angle | 1 | 2018 | 68 | 0.180 |
Why?
| | Glaucoma | 1 | 2019 | 140 | 0.180 |
Why?
| | Recovery of Function | 1 | 2019 | 571 | 0.160 |
Why?
| | Population Surveillance | 2 | 2011 | 409 | 0.160 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 338 | 0.160 |
Why?
| | Risk Factors | 6 | 2019 | 8467 | 0.160 |
Why?
| | Logistic Models | 2 | 2019 | 1984 | 0.160 |
Why?
| | Case-Control Studies | 2 | 2020 | 3225 | 0.160 |
Why?
| | Disease Management | 1 | 2019 | 559 | 0.150 |
Why?
| | Disease Outbreaks | 2 | 2008 | 285 | 0.150 |
Why?
| | Research Design | 1 | 2019 | 834 | 0.140 |
Why?
| | Condoms | 2 | 2004 | 124 | 0.140 |
Why?
| | Skin Neoplasms | 1 | 2019 | 682 | 0.140 |
Why?
| | Prevalence | 4 | 2020 | 2225 | 0.130 |
Why?
| | Melanoma | 1 | 2019 | 656 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2020 | 4151 | 0.130 |
Why?
| | Sexual Behavior | 4 | 2004 | 407 | 0.130 |
Why?
| | Clinical Competence | 1 | 2019 | 870 | 0.130 |
Why?
| | Cohort Studies | 4 | 2020 | 4560 | 0.120 |
Why?
| | Internship and Residency | 1 | 2019 | 857 | 0.110 |
Why?
| | Diagnostic Errors | 1 | 2011 | 158 | 0.110 |
Why?
| | Shellfish Poisoning | 1 | 2009 | 1 | 0.110 |
Why?
| | Vibrio Infections | 1 | 2009 | 2 | 0.110 |
Why?
| | Shellfish | 1 | 2009 | 5 | 0.110 |
Why?
| | Food Microbiology | 1 | 2009 | 25 | 0.110 |
Why?
| | Adult | 13 | 2020 | 30359 | 0.110 |
Why?
| | Food Industry | 1 | 2009 | 15 | 0.110 |
Why?
| | Mortality | 1 | 2011 | 294 | 0.100 |
Why?
| | Cause of Death | 1 | 2011 | 365 | 0.100 |
Why?
| | Primary Prevention | 1 | 2011 | 218 | 0.100 |
Why?
| | Adolescent | 6 | 2020 | 17541 | 0.100 |
Why?
| | Cryptosporidiosis | 1 | 2008 | 11 | 0.100 |
Why?
| | Prospective Studies | 1 | 2019 | 5605 | 0.100 |
Why?
| | Inflammation | 1 | 2019 | 2171 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 864 | 0.100 |
Why?
| | Tomography, Optical Coherence | 2 | 2019 | 117 | 0.100 |
Why?
| | Disease Reservoirs | 1 | 2007 | 19 | 0.100 |
Why?
| | Proportional Hazards Models | 1 | 2011 | 1072 | 0.090 |
Why?
| | Maternal-Child Health Centers | 1 | 2007 | 7 | 0.090 |
Why?
| | Infant | 5 | 2020 | 7629 | 0.090 |
Why?
| | Gastroenteritis | 1 | 2008 | 57 | 0.090 |
Why?
| | Horses | 1 | 2007 | 70 | 0.090 |
Why?
| | Culicidae | 1 | 2007 | 34 | 0.090 |
Why?
| | Health Services Administration | 1 | 2007 | 8 | 0.090 |
Why?
| | Sentinel Surveillance | 1 | 2007 | 41 | 0.090 |
Why?
| | Medicare | 1 | 2011 | 472 | 0.090 |
Why?
| | Postoperative Complications | 1 | 2019 | 2086 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2033 | 0.090 |
Why?
| | Chickens | 1 | 2007 | 174 | 0.090 |
Why?
| | Incidence | 4 | 2019 | 2317 | 0.090 |
Why?
| | Relief Work | 1 | 2007 | 20 | 0.090 |
Why?
| | Telephone | 1 | 2008 | 160 | 0.090 |
Why?
| | Birds | 1 | 2007 | 87 | 0.090 |
Why?
| | Geography | 1 | 2007 | 192 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 915 | 0.090 |
Why?
| | Disasters | 1 | 2007 | 77 | 0.080 |
Why?
| | Databases, Factual | 1 | 2011 | 1130 | 0.080 |
Why?
| | Health Care Surveys | 1 | 2008 | 586 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 1913 | 0.080 |
Why?
| | Immunoglobulins | 1 | 2006 | 158 | 0.080 |
Why?
| | Patient Discharge | 1 | 2011 | 624 | 0.080 |
Why?
| | Ganglionic Stimulants | 1 | 2005 | 12 | 0.080 |
Why?
| | Immunization Programs | 1 | 2007 | 189 | 0.080 |
Why?
| | Needs Assessment | 1 | 2007 | 321 | 0.080 |
Why?
| | Environment | 1 | 2007 | 426 | 0.080 |
Why?
| | Smoking | 1 | 2013 | 1538 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2011 | 589 | 0.080 |
Why?
| | Infant, Newborn | 3 | 2020 | 4741 | 0.070 |
Why?
| | Young Adult | 4 | 2020 | 10261 | 0.070 |
Why?
| | Diabetes Mellitus | 1 | 2011 | 852 | 0.070 |
Why?
| | Attitude to Health | 1 | 2007 | 390 | 0.070 |
Why?
| | Child, Preschool | 4 | 2020 | 9106 | 0.070 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 976 | 0.070 |
Why?
| | Gonorrhea | 1 | 2003 | 51 | 0.070 |
Why?
| | Health Surveys | 2 | 2021 | 490 | 0.070 |
Why?
| | Tobacco Use Disorder | 1 | 2005 | 229 | 0.070 |
Why?
| | Nicotine | 1 | 2005 | 251 | 0.060 |
Why?
| | Child | 4 | 2020 | 15648 | 0.060 |
Why?
| | Smoking Cessation | 1 | 2005 | 339 | 0.060 |
Why?
| | Dissent and Disputes | 1 | 2021 | 12 | 0.060 |
Why?
| | European Continental Ancestry Group | 1 | 2007 | 1337 | 0.060 |
Why?
| | African Americans | 1 | 2007 | 1040 | 0.060 |
Why?
| | Crowding | 1 | 2021 | 40 | 0.060 |
Why?
| | Vision, Binocular | 1 | 2020 | 13 | 0.060 |
Why?
| | Time Factors | 3 | 2019 | 7066 | 0.060 |
Why?
| | Myanmar | 1 | 2020 | 5 | 0.060 |
Why?
| | Bangladesh | 1 | 2020 | 29 | 0.060 |
Why?
| | Myotomy | 1 | 2020 | 12 | 0.060 |
Why?
| | Rupture | 1 | 2020 | 90 | 0.060 |
Why?
| | Eye Movements | 1 | 2020 | 80 | 0.050 |
Why?
| | Risk-Taking | 1 | 2003 | 347 | 0.050 |
Why?
| | Canada | 1 | 2020 | 301 | 0.050 |
Why?
| | Biomarkers | 2 | 2020 | 3163 | 0.050 |
Why?
| | Health Education | 1 | 2003 | 318 | 0.050 |
Why?
| | Remission, Spontaneous | 1 | 2019 | 40 | 0.050 |
Why?
| | Pyrimidinones | 1 | 2019 | 79 | 0.050 |
Why?
| | Microscopy, Acoustic | 1 | 2018 | 11 | 0.050 |
Why?
| | Ophthalmoscopy | 1 | 2018 | 24 | 0.050 |
Why?
| | Fluorescein Angiography | 1 | 2019 | 102 | 0.050 |
Why?
| | Preoperative Period | 1 | 2019 | 109 | 0.050 |
Why?
| | Axial Length, Eye | 1 | 2018 | 9 | 0.050 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 11 | 0.050 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.050 |
Why?
| | Pseudophakia | 1 | 2018 | 11 | 0.050 |
Why?
| | Prosthesis Design | 1 | 2020 | 259 | 0.050 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 515 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2019 | 670 | 0.050 |
Why?
| | Ambulatory Care Facilities | 3 | 2004 | 204 | 0.050 |
Why?
| | Physical Examination | 1 | 2019 | 239 | 0.050 |
Why?
| | Gestational Age | 1 | 2019 | 713 | 0.040 |
Why?
| | Birth Weight | 1 | 2019 | 390 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2020 | 8608 | 0.040 |
Why?
| | Proteomics | 1 | 2020 | 708 | 0.040 |
Why?
| | Program Evaluation | 2 | 2011 | 819 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1587 | 0.040 |
Why?
| | Child Abuse | 1 | 2019 | 478 | 0.040 |
Why?
| | Proteins | 1 | 2020 | 950 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 802 | 0.030 |
Why?
| | Animals | 3 | 2009 | 34264 | 0.030 |
Why?
| | Legionellosis | 1 | 2011 | 2 | 0.030 |
Why?
| | Prognosis | 1 | 2019 | 3289 | 0.030 |
Why?
| | Haemophilus Infections | 1 | 2011 | 24 | 0.030 |
Why?
| | Phenotype | 1 | 2019 | 2862 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1329 | 0.030 |
Why?
| | Whooping Cough | 1 | 2011 | 42 | 0.030 |
Why?
| | Medical Audit | 1 | 2011 | 81 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2011 | 143 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2011 | 99 | 0.030 |
Why?
| | Cryptosporidium | 1 | 2008 | 12 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2011 | 265 | 0.020 |
Why?
| | Caliciviridae Infections | 1 | 2008 | 19 | 0.020 |
Why?
| | Norovirus | 1 | 2008 | 25 | 0.020 |
Why?
| | Aid to Families with Dependent Children | 1 | 2007 | 3 | 0.020 |
Why?
| | Faculty | 1 | 2008 | 101 | 0.020 |
Why?
| | Family Characteristics | 1 | 2008 | 146 | 0.020 |
Why?
| | Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2007 | 77 | 0.020 |
Why?
| | Medically Uninsured | 1 | 2007 | 132 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 1912 | 0.020 |
Why?
| | Maryland | 1 | 2005 | 40 | 0.020 |
Why?
| | Pharmaceutical Preparations | 1 | 2007 | 147 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2009 | 512 | 0.020 |
Why?
| | Administration, Topical | 1 | 2005 | 153 | 0.020 |
Why?
| | Urban Health Services | 1 | 2004 | 68 | 0.020 |
Why?
| | Acute Disease | 1 | 2007 | 978 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2008 | 587 | 0.020 |
Why?
| | Syphilis | 1 | 2003 | 29 | 0.020 |
Why?
| | Office Visits | 1 | 2003 | 99 | 0.020 |
Why?
| | Mothers | 1 | 2007 | 534 | 0.020 |
Why?
| | Administration, Oral | 1 | 2005 | 812 | 0.020 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2003 | 245 | 0.010 |
Why?
| | Urban Population | 1 | 2004 | 408 | 0.010 |
Why?
| | Risk | 1 | 2004 | 952 | 0.010 |
Why?
| | HIV Infections | 1 | 2003 | 2101 | 0.010 |
Why?
|
|
Patnaik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|